KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Guardant Health (GH) Research & Development (2017 - 2025)

Guardant Health's Research & Development history spans 9 years, with the latest figure at $98.3 million for Q4 2025.

  • For Q4 2025, Research & Development rose 5.05% year-over-year to $98.3 million; the TTM value through Dec 2025 reached $364.2 million, up 4.73%, while the annual FY2025 figure was $364.2 million, 4.73% up from the prior year.
  • Research & Development for Q4 2025 was $98.3 million at Guardant Health, up from $90.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $106.6 million in Q4 2022 and bottomed at $55.5 million in Q1 2021.
  • The 5-year median for Research & Development is $88.0 million (2025), against an average of $85.8 million.
  • The largest annual shift saw Research & Development soared 95.8% in 2021 before it fell 15.69% in 2023.
  • A 5-year view of Research & Development shows it stood at $73.0 million in 2021, then surged by 45.96% to $106.6 million in 2022, then fell by 15.69% to $89.9 million in 2023, then increased by 4.1% to $93.5 million in 2024, then grew by 5.05% to $98.3 million in 2025.
  • Per Business Quant, the three most recent readings for GH's Research & Development are $98.3 million (Q4 2025), $90.0 million (Q3 2025), and $87.4 million (Q2 2025).